Cancer Drugs Market Research Reports

Titlepublishedprice

Perjeta (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023

By GlobalData
"......t treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line m......"
30-Sep-2014$3495

Kadcyla (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023

By GlobalData
"......t treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line m......"
30-Sep-2014$3495

Tykerb (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023

By GlobalData
"...... treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line me......"
30-Sep-2014$3495

Neratinib (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023

By GlobalData
"......ent treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line......"
30-Sep-2014$3495

PharmaPoint: HER2-Positive Breast Cancer – 5EU Drug Forecast and Market Analysis to 2023

By GlobalData
"......tiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. As in the other seven countries covered in this report, Herceptin is the market leader in France, since it was the first HER2-targe......"
30-Sep-2014$6995

PharmaPoint: HER2-Positive Breast Cancer – US Drug Forecast and Market Analysis to 2023

By GlobalData
"......tiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. The high incidence of HER2-positive breast cancer in the US, almost equaling that of the entire 5EU, and the high treatment rates i......"
30-Sep-2014$4995

PharmaPoint: HER2-Positive Breast Cancer – Japan Drug Forecast and Market Analysis to 2023

By GlobalData
"......tiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. In 2013, Herceptin was the market leader, taking 92% of the Japanese market. This is due to the fact that it is the most establishe......"
30-Sep-2014$4995

PharmaPoint: HER2-Positive Breast Cancer – China Drug Forecast and Market Analysis to 2023

By GlobalData
"......tiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. Currently, treatment rates for HER2-positive breast cancer in China are low, with Roche reporting that approximately 30% of patient......"
30-Sep-2014$4995

Herceptin (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023

By GlobalData
"......ent treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third, and fourth-line......"
30-Sep-2014$3495

Aprepitant – Comprehensive patent search

By Ark Patent Intelligence
"......hly trained, qualified staff using proprietary searching techniques, you won't need to worry about missing patents or updating data. And that means your IP staff will be freed up to concentrate on your business, rather than getting bogged down in pat......"
16-Sep-2014$7500
Live Chat
Live Chat by Comm100